Posted inClinical Updates
Safety, Tolerability, and Efficacy of Bepranemab in Prodromal-to-Mild Alzheimer’s Disease: Insights from a Phase 2 Randomized Controlled Trial
This comprehensive review evaluates bepranemab's safety, tolerability, and efficacy in prodromal-to-mild Alzheimer's disease, highlighting a recent phase 2 RCT showing no significant cognitive benefit despite a favorable safety profile, and discusses future directions for tau-targeted therapies.
